Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
14 studies found for:    Open Studies | "Carcinoma, Merkel Cell"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Carcinoma, Merkel Cell"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Avelumab in Subjects With Merkel Cell Carcinoma (JAVELIN Merkel 200)
Condition: Carcinoma, Merkel Cell
Intervention: Drug: Avelumab
2 Recruiting Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer
Conditions: Recurrent Merkel Cell Carcinoma;   Stage IIIA Merkel Cell Carcinoma;   Stage IIIB Merkel Cell Carcinoma;   Stage IV Merkel Cell Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
3 Recruiting QUILT-3.009: Study of aNK (Activated NK-92, Formerly Neukoplast) Infusions in Patients With Unresectable Stage III (IIIB) or Distant Metastatic (IV) Merkel Cell Carcinoma (MCC)
Conditions: Stage IIIB Merkel Cell Carcinoma;   Stage IV Merkel Cell Carcinoma
Intervention: Biological: aNK
4 Recruiting MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma
Condition: Merkel Cell Carcinoma
Intervention: Drug: MLN0128
5 Recruiting Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With 3 mg/kg BW Ipilimumab (Yervoy®) Versus Observation
Condition: Merkel Cell Carcinoma
Intervention: Drug: Ipilimumab
6 Unknown  F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma
Condition: Merkel Cell Carcinoma
Interventions: Drug: Arm A: F16IL2 in combination with paclitaxel;   Drug: Arm B: Paclitaxel
7 Recruiting Treatment of Unresecable and/or Metastatic Merkel Cell Carcinoma by Somatostatine Analogues
Condition: Carcinoma, Merkel Cell
Intervention: Drug: Lanreotide
8 Recruiting A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors
Conditions: Melanoma;   Merkel Cell Carcinoma;   Other Solid Tumors
Interventions: Drug: TALIMOGENE LAHERPAREPVEC (TVEC);   Radiation: Hypofractionated Radiotherapy
9 Recruiting Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma
Conditions: Merkel Cell Polyomavirus Infection;   Stage IV Merkel Cell Carcinoma
Interventions: Drug: Avelumab;   Other: Laboratory Biomarker Analysis;   Biological: MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells;   Radiation: Radiation Therapy;   Biological: Recombinant Interferon Beta
10 Recruiting Studies of Dermatologic Diseases Biospecimen Acquisition Protocol
Conditions: Dermatologic Conditions;   Healthy Volunteers;   Normal Volunteers;   Carcinoma, Merkel Cell
11 Not yet recruiting Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
Conditions: Functional Pancreatic Neuroendocrine Tumor;   Malignant Somatostatinoma;   Merkel Cell Carcinoma;   Metastatic Adrenal Gland Pheochromocytoma;   Metastatic Carcinoid Tumor;   Multiple Endocrine Neoplasia Type 1;   Multiple Endocrine Neoplasia Type 2A;   Multiple Endocrine Neoplasia Type 2B;   Neuroendocrine Neoplasm;   Non-Functional Pancreatic Neuroendocrine Tumor;   Pancreatic Glucagonoma;   Pancreatic Insulinoma;   Recurrent Adrenal Cortex Carcinoma;   Recurrent Adrenal Gland Pheochromocytoma;   Recurrent Merkel Cell Carcinoma;   Somatostatin-Producing Neuroendocrine Tumor;   Stage III Adrenal Cortex Carcinoma;   Stage III Thyroid Gland Medullary Carcinoma;   Stage IIIA Merkel Cell Carcinoma;   Stage IIIB Merkel Cell Carcinoma;   Stage IV Adrenal Cortex Carcinoma;   Stage IV Merkel Cell Carcinoma;   Stage IVA Thyroid Gland Medullary Carcinoma;   Stage IVB Thyroid Gland Medullary Carcinoma;   Stage IVC Thyroid Gland Medullary Carcinoma;   Thymic Carcinoid Tumor;   VIP-Producing Neuroendocrine Tumor;   Well Differentiated Adrenal Cortex Carcinoma;   Zollinger Ellison Syndrome
Interventions: Drug: Capecitabine;   Drug: Temozolomide;   Drug: Veliparib;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
12 Not yet recruiting PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers
Conditions: Neuroendocrine Tumors;   Carcinoma, Small Cell Lung;   Carcinoma, Large Cell Lung;   Merkel Cell Carcinoma;   Pheochromocytoma;   Paraganglioma;   Thyroid Cancer, Medullary;   Neuroendocrine Carcinoma
Intervention: Drug: PEN-221
13 Recruiting Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
Conditions: Solid Tumors;   Mycosis Fungoides;   Melanoma;   Merkel-cell Carcinoma;   Squamous Cell Carcinoma;   Breast Carcinoma;   Human Papillomavirus-Related Malignant Neoplasm;   Soft Tissue Sarcoma
Intervention: Drug: TTI-621
14 Not yet recruiting A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers
Conditions: Head and Neck Squamous Cell Carcinoma;   Breast Cancer;   Sarcoma;   Merkel Cell Carcinoma;   Cutaneous T-Cell Lymphoma;   Melanoma;   Renal Cancer;   Bladder Cancer;   Prostate Cancer
Interventions: Drug: Durvalumab;   Drug: Tremelimumab;   Drug: Poly ICLC

Indicates status has not been verified in more than two years